STOCK TITAN
  1. Home
  2. Sec-filings
  3. KRYS
  4. [Form 4] Krystal Biotech, Inc. Insider Trading Activity

25K-share sale by Krystal Biotech (NASDAQ: KRYS) R&D head

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Krystal Biotech, Inc. director and President, R&D Suma Krishnan reported open-market sales of 25,000 shares of common stock. The transactions took place on June 4, 2026 in multiple trades at prices generally ranging from about $300.75 to $311.65 per share.

The filing states that these sales were made under a pre-established Rule 10b5-1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to run until December 4, 2026 unless completed earlier. Krishnan also reports indirect ownership of 50,000 shares through the Krishnan Family Trust and 90,000 shares through the Krishnan Spousal Trust.

Positive

  • None.

Negative

  • None.
Insider Krishnan Suma
Role President, R&D
Sold 25,000 shs ($7.70M)
Type Security Shares Price Value
Sale Common Stock 320 $300.75 $96K
Sale Common Stock 593 $302.2508 $179K
Sale Common Stock 247 $303.1703 $75K
Sale Common Stock 400 $304.8939 $122K
Sale Common Stock 480 $305.865 $147K
Sale Common Stock 1,348 $307.0948 $414K
Sale Common Stock 12,729 $307.8066 $3.92M
Sale Common Stock 3,803 $308.8898 $1.17M
Sale Common Stock 2,801 $309.9451 $868K
Sale Common Stock 2,039 $310.937 $634K
Sale Common Stock 240 $311.65 $75K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,402,835 shares (Direct, null); Common Stock — 90,000 shares (Indirect, By Krishnan Spousal Trust)
Footnotes (1)
  1. The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025, and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. The transaction was executed in multiple trades ranging from $302.05 to $303.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $303.05 to $303.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $304.07 to $304.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $305.19 to $306.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $306.38 to $307.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $307.38 to $308.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $308.38 to $309.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $309.43 to $310.38. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $310.44 to $311.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $311.50 to $311.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
Shares sold 25,000 shares Open-market sales on June 4, 2026
Highest reported sale price $311.65/share Common stock sale on June 4, 2026
Lowest reported sale price $300.75/share Common stock sale on June 4, 2026
Indirect holdings – Krishnan Family Trust 50,000 shares Common stock held via Krishnan Family Trust
Indirect holdings – Krishnan Spousal Trust 90,000 shares Common stock held via Krishnan Spousal Trust
Rule 10b5-1 trading plan regulatory
"The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
irrevocable trust financial
"Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan..."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
co-trustee financial
"Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Krishnan Suma
(Last)(First)(Middle)
C/O KRYSTAL BIOTECH, INC.
2100 WHARTON STREET, SUITE 701
(Street)
PITTSBURGH PENNSYLVANIA 15203
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
President, R&D
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026S(1)320(2)D$300.751,402,835D
Common Stock06/04/2026S593D$302.2508(3)1,402,242D
Common Stock06/04/2026S247D$303.1703(4)1,401,995D
Common Stock06/04/2026S400D$304.8939(5)1,401,595D
Common Stock06/04/2026S480D$305.865(6)1,401,115D
Common Stock06/04/2026S1,348D$307.0948(7)1,399,767D
Common Stock06/04/2026S12,729D$307.8066(8)1,387,038D
Common Stock06/04/2026S3,803D$308.8898(9)1,383,235D
Common Stock06/04/2026S2,801D$309.9451(10)1,380,434D
Common Stock06/04/2026S2,039D$310.937(11)1,378,395D
Common Stock06/04/2026S240D$311.65(12)1,378,155D
Common Stock90,000IBy Krishnan Spousal Trust(13)
Common Stock50,000IBy Krishnan Family Trust(14)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
2. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025, and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.
3. The transaction was executed in multiple trades ranging from $302.05 to $303.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
4. The transaction was executed in multiple trades ranging from $303.05 to $303.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
5. The transaction was executed in multiple trades ranging from $304.07 to $304.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
6. The transaction was executed in multiple trades ranging from $305.19 to $306.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
7. The transaction was executed in multiple trades ranging from $306.38 to $307.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
8. The transaction was executed in multiple trades ranging from $307.38 to $308.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
9. The transaction was executed in multiple trades ranging from $308.38 to $309.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
10. The transaction was executed in multiple trades ranging from $309.43 to $310.38. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
11. The transaction was executed in multiple trades ranging from $310.44 to $311.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
12. The transaction was executed in multiple trades ranging from $311.50 to $311.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
13. Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
14. Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
Remarks:
/s/ Suma M. Krishnan06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Suma Krishnan report for Krystal Biotech (KRYS)?

Suma Krishnan reported selling 25,000 shares of Krystal Biotech common stock in open-market transactions on June 4, 2026. The trades were executed in multiple blocks at prices around $300–$312 per share and disclosed on a Form 4 insider filing.

At what prices were the KRYS shares sold in Suma Krishnan’s latest Form 4?

The disclosed sales occurred in multiple trades with weighted average prices from about $300.75 to $311.65 per share. Several footnotes note narrower trading ranges within that band, with Krishnan undertaking to provide exact trade-by-trade details upon request to relevant parties.

Was Suma Krishnan’s KRYS share sale done under a Rule 10b5-1 plan?

Yes. The filing states the sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. The plan commenced on December 4, 2025 and is scheduled to terminate by December 4, 2026 or earlier once all covered shares are sold.

How many Krystal Biotech shares does Suma Krishnan report as indirectly owned?

The Form 4 reports 50,000 shares held by the Krishnan Family Trust and 90,000 shares held by the Krishnan Spousal Trust. The filing notes that the family trust is jointly controlled by Krishnan and her spouse, while the spousal trust has shared voting and investment power with a third-party co-trustee.

What role does Suma Krishnan hold at Krystal Biotech (KRYS)?

According to the Form 4, Suma Krishnan is both a director and an officer of Krystal Biotech, serving as President, R&D. The filing also marks her as a ten percent owner, reflecting a significant stake in the company alongside her board and executive responsibilities.

How many share sales are reported in Suma Krishnan’s June 4, 2026 Form 4 for KRYS?

The transaction summary shows 11 sale entries totaling 25,000 shares of Krystal Biotech common stock. Each entry reflects a separate open-market sale code "S" with its own weighted average sale price and a footnote offering to provide detailed trade-level pricing information upon request.